Androgens and the molecular epidemiology of prostate cancer

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 15, Issue 3, 2008, Pages 261-270

  Chu, Lisa W ^a   Reichardt, Juergen K V ^b   Hsing, Ann W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Androgen metabolism; Androgen signaling; Prostate cancer epidemiology

Indexed keywords

17BETA HYDROXYSTEROID DEHYDROGENASE 2; 17BETA HYDROXYSTEROID DEHYDROGENASE 3; 3 BETA HYDROXYSTEROID DEHYDROGENASE 1; 3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; ANDROGEN; ANDROGEN RECEPTOR; AROMATASE; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 17; CYTOCHROME P450 17A1; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; GLYCOSYLTRANSFERASE; HYDROXYSTEROID DEHYDROGENASE; HYDROXYSTEROID DEHYDROGENASE 17B1; SEX HORMONE BINDING GLOBULIN; STEROID 5ALPHA REDUCTASE 2; STEROID RECEPTOR COACTIVATOR 3; SULFOTRANSFERASE; URIDINE DIPHOSPHATE;

ANDROGEN BLOOD LEVEL; ANDROGEN METABOLISM; CANCER RISK; CHROMOSOME 8Q; CHROMOSOME 8Q24; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; NONHUMAN; PROSTATE CANCER; REVIEW;

ANDROGENS; EPIDEMIOLOGY, MOLECULAR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; POLYMORPHISM, GENETIC; PROSTATE; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 42649090792     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e3282febcf6     Document Type: Review

References (81)

1. Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci 2006; 11:1388-1413.
2. Chokkalingam AP, Stanczyk FZ, Reichardt JKV, Hsing AW. Molecular epidemiology of prostate cancer: hormone-related genetic loci. Front Biosci 2007; 12:3436-3460.
3. Hsing AW, Reichardt JK, Stanczyk FZ. Hormones and prostate cancer: current perspectives and future directions. Prostate 2002; 52:213-235.
4. Pollard MM, Luckert PPH, Schmidt MMA. Induction of prostate adenocarcinomas in Lobund Wistar rats by testosterone. Prostate 1982; 3:563-568.
5. Huggins C, Hodges CV. Studies on prostatic cancer I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1:293-297.
6. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005; 294:238-244.
7. Endogenous Hormones and Prostate Cancer Collaborative Group. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies [abstract]. J Natl Cancer Inst 2008; 100:170-183. Pooled analysis of 18 prospective studies (total of 3886 prostate cancer cases and 6438 controls) on serum androgens and prostate cancer risk showed no association between total androgen levels and disease risk. A suggestive inverse relationship between serum SHBG levels and prostate cancer risk was observed.
8. Weiss JM, Huang WY, Rinaldi S, et al. Endogenous sex hormones and the risk of prostate cancer: a prospective study. Int J Cancer 2008 [Epub ahead of print]. In a population of 727 incident Caucasian prostate cancer cases and 889 matched controls nested in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, prostate cancer risks were not associated with serum androgens or SHBG. There was an observed increase in prostate cancer risk with increasing testosterone-to-SHBG ratio, which was restricted mainly to risk in older men (-≥65 years) and particularly for aggressive disease.
9. Hsing AW, Sakoda LC, Chua SC Jr. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 2007; 86:843S-857S.
10. Ntais C, Polycarpou A, Ioannidis JPA. Association of the CYP17 gene polymorphism with the risk of prostate cancer:a meta-analysis. Cancer Epidemiol Biomarkers Prev 2003; 12:120-126.
11. Setiawan VW, Schumacher FR, Haiman CA, et al. CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Epidemiol Biomarkers Prev 2007; 16:2237-2246. Analysis using a two-step haplotype approach for genotyping 29 common polymorphisms in CYP17, did not demonstrate an overall gene effect of CYP17 on prostate cancer risk in a population of 8138 prostate cancer cases and 9033 controls (predominantly men of European descent). Borderline significant associations with prostate cancer were seen for rs2486758 and rs6892, although the effect size was very close to an odds ratio of 1.
12. Hamada A, Danesi R, Price DK, et al. Association of a CYP17 polymorphism with overall survival in caucasian patients with androgen-independent prostate cancer. Urology 2007; 70:217-220.
13. Lindstrom S, Adami HO, Balter KA, et al. Inherited variation in hormone-regulating genes and prostate cancer survival. Clin Cancer Res 2007; 13:5156-5161.
14. Sarma AV, Dunn RL, Lange LA, et al. Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study. Prostate 2008; 68:296-305. In a population of African-Americans in the Flint Men's Health Study (131 cases and 342 controls), variations in CYP17, CYP3A4, CYP19A1, SDR5A2, IGF1, and IGFBP3 were assessed for associations with prostate cancer. Three of four variants in CYP17 were associated with prostate cancer risk; all three variants reside in exons or at the 50 untranslated region.
15. Kraft P, Pharoah P, Chanock SJ, et al. Genetic variation in the HSD17B1 gene and risk of prostate cancer. PLoS Genetics 2005; 1:e68.
16. Cunningham JM, Hebbring SJ, McDonnell SK, et al. Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Cancer Epidemiol Biomarkers Prev 2007; 16:969-978.
17. n repeat polymorphism within the third intron was associated with increased risk for prostate cancer among all patients and Caucasians but not in African-Americans. Also, no associations were seen for the SRD5A2 V89L variation. Most of the prostate cancer risk associated with the intron 3 HSD3B2 short allele was confined to the SRD5A2 89L variant subgroup and indicated that in combination these polymorphisms may be associated with an increased risk of aggressive disease (Gleason >7).
18. Park JY, Tanner J-P, Sellers TA, et al. Association between polymorphisms in HSD3B1 and UGT2B17 and prostate cancer risk. Urology 2007; 70:374-379. In a case-control study of 356 prostate cancer cases and 363 age-matched controls, the UGT2B17 null polymorphism was associated with overall prostate cancer risk, while the HSD3B1 codon 367 variation was associated with prostate cancer risk among White men with a family history of this disease. Risk for prostate cancer associated with the UGT2B17 null polymorphism was further elevated among individuals with HSD3B1 variant.
19. Makridakis NM, Buchanan G, Tilley W, Reichardt JK. Androgen metabolic genes in prostate cancer predisposition and progression. Front Biosci 2005; 10:2892-2903.
20. Ntais C, Polycarpou A, Ioannidis JP. SRD5A2 gene polymorphisms and the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2003; 12:618-624.
21. Wu AH, Whittemore AS, Kolonel LN, et al. Lifestyle determinants of 5-alpha-reductase metabolites in older African-American, white, and Asian-American men. Cancer Epidemiol Biomarkers Prev 2001; 10:533-538.
22. Cicek MS, Conti DV, Curran A, et al. Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR. Prostate 2004; 59:69-76.
23. Cussenot O, Azzouzi AR, Nicolaiew N, et al. Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors. Eur Urol 2007; 52:1082-1087.
24. Nam RK, Toi A, Vesprini D, et al. V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression. Urology 2001; 57:199-204.
25. Giwercman YL, Abrahamsson P-A, Giwercman A, et al. The 5[alpha]-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population. Eur Urol 2005; 48:679-685.
26. Berndt SI, Chatterjee N, Huang W-Y, et al. Variant in sex hormone-binding globulin gene and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2007; 16:165-168. The largest epidemiologic study of SHBG variants and prostate cancer risk shows that a D354N variant, which has putative function, is associated with an increased risk for prostate cancer among Whites. This case-control study (1257 cases and 1785 controls) was nested in the PLCO trial.
27. Belanger A, Pelletier G, Labrie F, et al. Inactivation of androgens by UDP-glucuronosyltransferase enzymes in humans. Trends Endocrinol Metab 2003; 14:473-479.
28. Barbier O, Lapointe H, El Alfy M, et al. Cellular localization of uridine diphosphoglucuronosyltransferase 2B enzymes in the human prostate by in situ hybridization and immunohistochemistry. J Clin Endocrinol Metab 2000; 85:4819-4826.
29. Chouinard S, Pelletier G, eacute, et al. Cellular specific expression of the androgen-conjugating enzymes UGT2B15 and UGT2B17 in the human prostate epithelium. Endocr Res 2004; 30:717-725.
30. Chouinard S, Barbier O, Belanger A. UDP-glucuronosyltransferase 2B15 (UGT2B15) and UGT2B17 enzymes are major determinants of the androgen response in prostate cancer LNCaP cells. J Biol Chem 2007; 282:33466-33474.
31. Park J, Chen L, Shade K, et al. Asp85tyr polymorphism in the udp-glucuronosyltransferase (UGT) 2B15 gene and the risk of prostate cancer. J Urol 2004; 171:2484-2488.
32. Park J, Chen L, Ratnashinge L, et al. Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men. Cancer Epidemiol Biomarkers Prev 2006; 15:1473-1478.
33. Gallagher CJ, Kadlubar FF, Muscat JE, et al. The UGT2B17 gene deletion polymorphismand risk of prostate cancer: a case-control study in Caucasians. Cancer Detect Prev 2007; 31:310-315. No association between a UGT2B17 deletion polymorphism, which is associated with a substantial reduction in glucuronication activity, and prostate cancer risk was observed in a case-control study of 411 Caucasian cases and 397 Caucasian controls.
34. Wilborn TW, Lang NP, Smith M, et al. Association of SULT2A1 allelic variants with plasma adrenal androgens and prostate cancer in African American men. J Steroid Biomchem Mol Biol 2006; 99:209-214.
35. Thomae BA, Eckloff BW, Freimuth RR, et al. Human sulfotransferase SULT2A1 pharmacogenetics: genotype-to-phenotype studies. Pharmacogenomics J 2002; 2:48-56.
36. He D, Meloche CA, Dumas NA, et al. Different subcellular localization of sulphotransferase 2B1b in human placenta and prostate. Biochem J 2004; 379:533-540.
37. He D, Falany CN. Inhibition of SULT2B1b expression alters effects of 3-beta-hydroxysteroids on cell proliferation and steroid hormone receptor expression in human LNCaP prostate cancer cells. Prostate 2007; 67:1318-1329.
38. Dehm SM, Tindall DJ. Molecular regulation of androgen action in prostate cancer. J Cell Biochem 2006; 99:333-344.
39. Culig Z, Hobisch A, Hittmair A, et al. Hyperactive androgen receptor in prostate cancer: what does it mean for new therapy concepts? Histol Histopathol 1997; 12:781-786.
40. Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 1994; 22:3181-3186.
41. Edwards A, Hammond HA, Jin L, et al. Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics 1992; 12:241-253.
42. Richter E, Srivastava S, Dobi A. Androgen receptor and prostate cancer. Prostate Cancer Prostatic Dis 2007; 10:114-118.
43. Heemers HV, Tindall DJ. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 2007; 28:778-808.
44. Hsing AW, Chokkalingam AP, Gao YT, et al. Polymorphic CAG/CAA repeat length in the AIB1/SRC-3 gene and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2002; 11:337-341.
45. Platz E, Giovannucci E, Brown M, et al. Amplified in breast cancer-1 glutamine repeat and prostate cancer risk. Prostate J 2000; 2:27-32.
46. Chung ACK, Zhou S, Liao L, et al. Genetic ablation of the amplified-in-breast cancer 1 inhibits spontaneous prostate cancer progression in mice. Cancer Res 2007; 67:5965-5975.
47. Saez JM, Forest MG, Morera AM, Bertrand J. Metabolic clearance rate and blood production rate of testosterone and dihydrotestosterone in normal subjects, during pregnancy, and in hyperthyroidism. J Clin Invest 1972; 51:1226-1234.
48. Vermeulen A, Ando S. Metabolic clearance rate and interconversion of androgens and the influence of the free androgen fraction. J Clin Endocrinol Metab 1979; 48:320-326.
49. Namkung PC, Stanczyk FZ, Cook MJ, et al. Half-life of plasma sex steroid-binding protein (SBP) in the primate. J Steroid Biochem 1989; 32:675-680.
50. Hammes A, Andreassen TK, Spoelgen R, et al. Role of endocytosis in cellular uptake of sex steroids. Cell 2005; 122:751-762.
51. Ellem SJ, Schmitt JF, Pedersen JS, et al. Local aromatase expression in human prostate is altered in malignancy. J Clin Endocrinol Metab 2004; 89:2434-2441.
52. Latil AG, Azzouzi R, Cancel GS, et al. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer 2001; 92:1130-1137.
53. Suzuki KK, Nakazato HH, Matsui HH, et al. Association of the genetic polymorphism of the CYP19 intron 4[TTTA]n repeat with familial prostate cancer risk in a Japanese population. Anticancer Res 2003; 23:4941-4946.
54. Cussenot O, Azzouzi AR, Nicolaiew N, et al. Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens. J Clin Oncol 2007; 25:3596-3602.
55. Li L, Cicek MS, Casey G, Witte JS. No association between a tetranucleotide repeat polymorphism of CYP19 and prostate cancer. Cancer Epidemiol Biomarkers Prev 2004; 13:2280-2281.
56. Modugno F, Weissfeld JL, Trump DL, et al. Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. Clin Cancer Res 2001; 7:3092-3096.
57. Fukatsu TT, Hirokawa YY, Araki TT, et al. Genetic polymorphisms of hormone-related genes and prostate cancer risk in the Japanese population. Anticancer Res 2004; 24:2431-2437.
58. Suzuki K, Nakazato H, Matsui H, et al. Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol-O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population. Cancer 2003; 98:1411-1416.
59. Douglas JA, Zuhlke KA, Beebe-Dimmer J, et al. Identifying susceptibility genes for prostate cancer-a family-based association study of polymorphisms in CYP17, CYP19, CYP11A1, and LH-{beta}. Cancer Epidemiol Biomarkers Prev 2005; 14:2035-2039.
60. Mononen N, Seppala EH, Duggal P, et al. Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors. Cancer Res 2006; 66:743-747.
61. Huang Y-C, Chen M, Lin M-W, et al. CYP19 TCT tri-nucleotide Del/Del genotype is a susceptibility marker for prostate cancer in a Taiwanese population. Urology 2007; 69:996-1000.
62. Cavalieri EL, Devanesan P, Bosland MC, et al. Catechol estrogen metabolites and conjugates in different regions of the prostate of Noble rats treated with 4-hydroxyestradiol: implications for estrogen-induced initiation of prostate cancer. Carcinogenesis 2002; 23:329-333.
63. Suzuki M, Mamun MR, Hara K, et al. The Val158Met polymorphism of the catechol-O-methyltransferase gene is associated with the PSA-progression-free survival in prostate cancer patients treated with estramustine phosphate. Eur Urol 2005; 48:752-759.
64. Suzuki M, Kurosaki T, Arai T, et al. The Val158Met polymorphism of the catechol-O-methyltransferase gene is not associated with the risk of sporadic or latent prostate cancer in Japanese men. Int J Urol 2007; 14:800-804.
65. Tanaka Y, Sasaki M, Shiina H, et al. Catechol-O-methyltransferase gene polymorphisms in benign prostatic hyperplasia and sporadic prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15:238-244.
66. Nock NL, Cicek MS, Li L, et al. Polymorphisms in estrogen bioactivation, detoxification and oxidative DNA base excision repair genes and prostate cancer risk. Carcinogenesis 2006; 27:1842-1848.
67. Freedman ML, Haiman CA, Patterson N, et al. Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci U S A 2006; 103:14068-14073.
68. Gudmundsson J, Sulem P, Manolescu A, et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 2007; 39:631-637. In an Icelandic case-control study of 1453 prostate cancer cases and 3064 controls, two genetic variants (rs1447295 and microsatellite marker DG8S737) in the 8q24 chromosomal region accounted for 11-13% of prostate cancer cases in individuals of European descent and 31% of cases in African-Americans. None of the risk variants is associated with a known gene.
69. Haiman CA, Patterson N, Freedman ML, et al. Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet 2007; 39:638-644. In a study population of 7518 men with and without prostate cancer from five populations, seven risk variants (rs13254738, rs6983561, Broad11934905, rs6983267, rs7000448, DG8S737, and rs10090154), five of them previously not described, spanning 430 kb of 8q24, each were independently associated with risk for prostate cancer. None of the prostate cancer risk variants aligns to a known gene or alters the coding sequence of an encoded protein.
70. Robbins C, Torres JB, Hooker S, et al. Confirmation study of prostate cancer risk variants at 8q24 in African Americans identifies a novel risk locus. Genome Res 2007; 17:1717-1722.
71. Schumacher FR, Feigelson HS, Cox DG, et al. A common 8q24 variant in prostate and breast cancer from a large nested case-control study. Cancer Res 2007; 67:2951-2956. A study of the overall association of the 8q24 rs1447295 risk variant with prostate cancer risks in a study population of 6637 prostate cancer cases and 7361 matched controls showed: (a) the rs1447295 marker was strongly associated with prostate cancer among Caucasians; (b) among African-Americans, the association was statistically significant in men diagnosed with prostate cancer at an early age and nonsignificant for those diagnosed at a later age; this difference in risk by age at diagnosis was not present among Caucasians; and (c) no statistically significant difference in risk was observed when the tumors were classified by Gleason score, stage, or mortality.
72. Severi G, Hayes VM, Padilla EJ, et al. The common variant rs1447295 on chromosome 8q24 and prostate cancer risk: results from an Australian population-based case-control study. Cancer Epidemiol Biomarkers Prev 2007; 16:610-612.
73. Suuriniemi M, Agalliu I, Schaid DJ, et al. Confirmation of a positive association between prostate cancer risk and a locus at chromosome 8q24. Cancer Epidemiol Biomarkers Prev 2007; 16:809-814.
74. Wang L, McDonnell SK, Slusser JP, et al. Two common chromosome 8q24 variants are associated with increased risk for prostate cancer. Cancer Res 2007; 67:2944-2950.
75. Witte JS. Multiple prostate cancer risk variants on 8q24. Nat Genet 2007; 39:579-580.
76. Yeager M, Orr N, Hayes RB, et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007; 39:645-649. In the CGEMS project with 550 000 SNPs in a nested case-control study (1172 cases and 1157 controls of European origin) of PLCO, an independent association of rs6983267 and the previously reported rs1447295, both at 8q24, with prostate cancer risk was observed; the two markers showed little evidence of linkage disequilibrium. A combined analysis with four additional studies (total: 4296 cases and 4299 controls) confirmed association with prostate cancer for rs6983267, and each variation remained significant in a joint analysis after adjustment for the other. The estimated population attributed risk for rs6983267 was higher than that for the locus marked by rs1447295 (21 vs. 9%).
77. Zheng SL, Sun J, Cheng Y, et al. Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst 2007; 99:1525-1533.
78. Zheng SL, Sun J, Wiklund F, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med 2008; 358:910-919.
79. Dudkowska MM, Jaworski TT, Grzelakowska-Sztabert BB, Manteuffel- Cymborowska MM. Androgen receptor and c-Myc transcription factors as putative partners in the in vivo cross-talk between androgen receptor-mediated and c-Met-mediated signalling pathways. Acta Biochim Pol 2007; 54:253-259.
80. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349:215-224.
81. Andriole GG, Bostwick DD, Brawley OO, et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 2004; 172:1314-1317.